Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin/metformin - Boehringer Ingelheim/Eli Lilly and Company

Next Previous
Drug Profile

Empagliflozin/metformin - Boehringer Ingelheim/Eli Lilly and Company

Alternative Names: BI-10773/metformin; Empagliflozin/metformin extended-release; Empagliflozin/metformin immediate-release; Gibtulio Met; Metformin/BI-10773; Metformin/empagliflozin; Metformin/empagliflozin extended-release; Metformin/empagliflozin immediate-release; Metformin/empagliflozin XR; Oboravo Met; Synjardy; Synjardy XR

Latest Information Update: 22 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly and Company
  • Class Antihyperglycaemics; Benzhydryl compounds; Biguanides; Cyclic ethers; Glucosides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 16 Jun 2026 Assertio Therapeutics has been acquired by Zydus Lifesciences
  • 22 Jun 2023 Registered for Type 2 diabetes mellitus (In adolescents, In children) in USA (PO)
  • 20 Jun 2023 Efficacy data from a phase III trial in Type-2 diabetes mellitus released by Boehringer Ingelheim

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top